Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8982210 | 0.97 | ABCB1 (0.52) | ABCB1KMT2AHTR7TMEM97SIGMAR1 | |
| Hydrochloric Acid SCHEMBL4234411 | 0.96 | ABCB1 (0.51) | ABCB1KMT2ATMEM97SIGMAR1 | |
| SCHEMBL13878296 | 0.87 | DRD2 (0.50) | ABCB1KMT2AHTR7TMEM97SIGMAR1 | |
| SCHEMBL2135663 | 0.87 | KMT2A (0.60) | ABCB1KMT2AHTR7TMEM97SIGMAR1 | |
| SCHEMBL2137287 | 0.85 | HTR7 (0.58) | ABCB1KMT2AHTR7TMEM97SIGMAR1 | |
| SCHEMBL10035519 | 0.85 | HTR7 (0.62) | HTR7 | |
| SCHEMBL2140476 | 0.85 | HTR7 (0.56) | ABCB1KMT2AHTR7TMEM97SIGMAR1 | |
| SCHEMBL2140293 | 0.84 | KMT2A (0.55) | ABCB1KMT2AHTR7TMEM97SIGMAR1 | |
| SCHEMBL10035609 | 0.84 | KMT2A (0.54) | ABCB1KMT2AHTR7TMEM97SIGMAR1 | |
| SCHEMBL10035585 | 0.84 | CCR1 (0.53) | ABCB1KMT2AHTR7TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148397-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-04-03 | — | — | US | disclosed |
| US-8148397-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-04-03 | — | — | US | disclosed |
| US-8148397-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-04-03 | — | — | US | disclosed |
| US-20090088450-A1 | 5-ht7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
| US-20090088450-A1 | 5-ht7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
| US-20090088450-A1 | 5-ht7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
| US-7211584-B2 | 5-HT7 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-01 | — | — | US | disclosed |
| US-7211584-B2 | 5-HT7 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-01 | — | — | US | disclosed |
| US-7211584-B2 | 5-HT7 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-01 | — | — | US | disclosed |
| US-20060040977-A1 | 5-HT7 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088450-A1 | 5-ht7 receptor antagonists | HTR7, HTR1A, HTR5A | ABCB1 551/4885KMT2A 2533/4885HTR7 1/4885 |
| US-20060040977-A1 | 5-HT7 receptor ligands | HTR7, HTR1A, HTR5A | ABCB1 669/4885KMT2A 2831/4885HTR7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.